Jasper Therapeutics (NASDAQ:JSPR) Receives “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $68.00 price target on the stock.

A number of other research firms have also recently commented on JSPR. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Evercore ISI reissued an “outperform” rating and set a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a report on Thursday, October 24th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target on the stock. Finally, JMP Securities reissued a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $73.38.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $22.12 on Monday. Jasper Therapeutics has a 1 year low of $5.02 and a 1 year high of $31.01. The stock has a market capitalization of $331.82 million, a price-to-earnings ratio of -4.67 and a beta of 2.18. The company’s 50 day simple moving average is $21.74 and its 200 day simple moving average is $20.67.

Hedge Funds Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its stake in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after purchasing an additional 1,698 shares during the last quarter. Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics during the 3rd quarter worth about $59,000. MetLife Investment Management LLC grew its position in shares of Jasper Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at about $251,000. Finally, Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics in the second quarter valued at about $300,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.